May 20, 2018 4:47 PM ET

Pharmaceuticals

Company Overview of Janssen Pharmaceutica NV

Company Overview

Janssen Pharmaceutica NV discovers, develops, and produces medicines and therapeutic solutions for diabetes, hepatitis, HIV, cancer, arthritis, dementia, and mental disorders. It offers fluid, semi-solid, and injectable medicines; and researches on neurosciences, infectious diseases and vaccines, oncology, immunology, and cardiovascular and metabolic disorders. The company was formerly known as N.V. Laboratoria Pharmaceutica Dr.C. Janssen and changed its name to Janssen Pharmaceutica NV in February 1964. Janssen Pharmaceutica NV was founded in 1934 and is based in Beerse, Belgium with research centers in Europe and the United States. Janssen Pharmaceutica NV operates as a subsidiary of Johns...

Turnhoutseweg 30

Beerse,  2340

Belgium

Founded in 1934

Phone:

32 1 460 21 11

Fax:

32 1 460 28 41

Key Executives for Janssen Pharmaceutica NV

Chief Executive Officer
Managing Director for Benelux
Compensation as of Fiscal Year 2017.

Janssen Pharmaceutica NV Key Developments

GenomeDx Biosciences Announces Research Collaboration with Janssen Pharmaceuticals to Evaluate the Decipher® Classifier and Decipher GRID® for Drug Development

GenomeDx Biosciences announced a research collaboration with Janssen Pharmaceuticals. As part of the agreement, GenomeDx will test samples using its genome-wide expression assay from multiple Janssen prostate cancer clinical trials to examine the association of prognostic and predictive signatures available on the Decipher GRID® platform with clinical outcomes.

Janssen Pharmaceutica NV Presents at 11th Annual European Life Sciences CEO Forum & Exhibition, Feb-26-2018

Janssen Pharmaceutica NV Presents at 11th Annual European Life Sciences CEO Forum & Exhibition, Feb-26-2018 . Venue: Hilton Zurich Airport Hotel, Hohenbuehlstrasse 10, Opfikon-Glattbrugg 8152, Zurich, Switzerland. Speakers: Julian Bertschinger, VP Janssen R&D, Head Therapeutic Platform Innovation.

Janssen Pharmaceutica NV Announces Results of Pivotal Phase 3 AMBER Study

Janssen Pharmaceutica, NV announced that the pivotal Phase 3 AMBER study achieved its primary endpoint, which focused on virologic response rate, and demonstrated that the investigational single-tablet regimen (STR) containing darunavir 800 mg, cobicistat 150 mg, emtricitabine 200 mg and tenofovir alafenamide 10 mg (D/C/F/TAF) was non-inferior to darunavir/cobicistat (D/C) plus emtricitabine and tenofovir disoproxil fumarate (F/TDF) in previously untreated human immunodeficiency virus type 1 (HIV-1) positive adults. The results will be presented on October 27 at the 16thEuropean AIDS Conference in Milan, Italy. AMBER is a Phase 3 randomized, double-blind, active-controlled, international, multi-center, non-inferiority study designed to assess the safety and efficacy of D/C/F/TAF versus the control in HIV-1 treatment-na negative patients. The control was comprised of two separate medications D/C plus F/TDF and patients were randomly assigned (362 D/C/F/TAF; 363 control). The primary endpoint was non-inferiority of the STR versus the control regarding the proportion of patients that achieved viral suppression (viral load [VL] of less than 50 copies per mL at 48 weeks per FDA Snapshot analysis). Reaching suppression of viral load (or the amount of HIV virus in the blood) is a key treatment goal for people living with HIV. Overall, the AMBER study met the primary endpoint, and D/C/F/TAF demonstrated non-inferiority versus the control group at 48 weeks.

Similar Private Companies By Industry

Company Name Region
Amakem NV Europe
Aminolabs SA Europe
Apotheek Delestre NV Europe
Apotheek Moons NV Europe
Apotheek Philips NV Europe

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
June 28, 2017
Portfolio of European OTC Products
\
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
Tax Management Inc United States
John F. Kennedy Center For The Performing Arts United States
NYC2012, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Janssen Pharmaceutica NV, please visit www.janssenbelgium.be. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.